Emerging Therapies in Geographic Atrophy

Ryan Haumschild, PharmD, MS, MBA, opens a discussion surrounding the disease landscape of geographic atrophy.

Geographic atrophy disease progression is explored by a panel of medical experts.

David Lally, MD, highlights risk factors associated with geographic atrophy.

Dr Haumschild leads a discussion surrounding comorbidities associated with geographic atrophy.

Maria Lopes, MD, MS, highlights the utilization of health care resources to optimize GA treatment impact.

GA treatment options in various steps in FDA approval process are discussed by a panel of medical experts.

Medical experts recap the DERBY and OAKS studies.

The GATHER1 and GATHER2 studies are highlighted.

Drs Lally and Khanani expand on key takeaways from the GATHER1 and GATHER2 studies.

Dr Lopes provides insights into payer considerations when navigating geographic atrophy treatment pathways.

Key opinion leaders discuss clinical and cost considerations for treating patients diagnosed with geographic atrophy.

Dr Khanani discusses how to monitor patients with geographic atrophy for adverse events.

In their final thoughts, the panelists explore the future of GA treatment strategies.